CN106397541A - Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome - Google Patents
Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome Download PDFInfo
- Publication number
- CN106397541A CN106397541A CN201610181324.9A CN201610181324A CN106397541A CN 106397541 A CN106397541 A CN 106397541A CN 201610181324 A CN201610181324 A CN 201610181324A CN 106397541 A CN106397541 A CN 106397541A
- Authority
- CN
- China
- Prior art keywords
- reverse
- density protein
- lps
- simulating peptide
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to an application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines or kits for treating LPS-induced respiratory distress syndrome, the sequence of the high-density protein mimic peptide is Ac-FAEKFKEAVKDYFAKFWD-NH2. The Reverse-D-4F can inhibit pulmonary edema of an LPS-induced rat lung injury model, inhibit in-vivo inflammatory factors, alveolar wall thickening and intercellular space erythrocyte and leucocyte infiltration, as well as the generation of lung vascular endothelial inflammation markers (ICAM-1, VCAN-1 and iNOS) and the endothelial marks (eNOS and vWF) are increased. Reverse-D-4F promotes mobilization of EPCS of the LPS-induced rat lung injury model, no matter whether in vitro or in vivo, the Reverse-D-4F can be used for repairing the injured function of the EPCS of the LPS-induced rat lung injury model.
Description
Technical field
The present invention relates to the application of high density lipoprotein simulating peptide Reverse-D-4F, specially treat LPS
Application in the medicine of Induced respiration Distress Syndrome.
Background technology
Adult respiratory distress syndrome (ARDS) is a kind of common clinical syndrome, has higher mortality rate,
Clinical manifestation is respiratory distress, difficulty, corrects anoxia by traditional oxygen therapy.The pathogenesis of ARDS can be divided into life
Thing and abiotic pathogen.Bio-pathogen includes antibacterial, virus, funguses, atypical pathogens and pernicious swollen
Tumor, rather than biopathogen includes acidic materials, medicine, toxic gas suck the injury related with mechanical ventilation.
Initially, the harmful substance such as endotoxin in blood circulation damages PCEC (PCEC), leads
Cause endothelial cell permeability to increase, and shrink and dead.After damaging about 2 hours, pulmonary interstitial edema occurs and sends out
Raw；After damaging 12 to 24 hours, intra-alveolar edema occurs.
Endothelial dysfunction and inflammation play important in the occurrence and development of adult respiratory distress syndrome
Effect.Bai Han etc. shows that survival rate is proportionate with endothelial progenitor cells (EPCs) clone's number.In LPS induction
Acute lung injury (ALI) rat model in find, transplantation of Endothelial Progenitor Cells can maintain alveolar capillary screen
The integrity of barrier, recovers vascular endothelial function, improves inflammatory conditions.Therefore, EPCs is in reparation ARDS
Skin lesion wound and suppression ARDS occur development to have important function.But, ARDS proinflammatory factor level in the patient
Improve (as OxLDL ELISA, IL-6, TNF-α α), the work(of EPCs in the infringement of these inflammatory factors
Can, including cell proliferation, migration and vascularization.These impaired endothelial progenitor cells cannot recover ARDS and suffer from
The impaired blood vessel endothelium system of person.Therefore, increase the quantity of endothelial progenitor cells, it is interior that mitigation inflammatory factor causes
Skin CFU-GM dysfunction may play a significant role in suppression ARDS development.
High density lipoprotein (HDL) has been demonstrated there is mobilization bone marrow EPCs, suppression EPCs apoptosis and promotion
EPCs is divided into the function of endotheliocyte.Apolipoprotein A-1 (apoA-I) is the important work(of high density lipoprotein
Energy property composition, has 243 kinds of aminoacid, has been demonstrated to improve the survival rate of rats with sepsis.Because apoA-I
Capability of lipid binding and its amphipathic helix structure have much relations, therefore the simulation according to this characteristics design recently
Peptide, this simulating peptide contains four phenylalanine residue (4F in hydrophobic surface；F represents Phenylalanine), and mould
Imitative A class amphipathic helix, this simulating peptide and apoA-I do not have sequence homology.It is reported that, 4F have antiinflammatory,
Antioxidation, improves the survival rate of rats with sepsis.Reverse-D-4F be according to
The simulating peptide of the reverse sequence synthesis of D-4F (Ac-DWFKAFYDKVAEKFKEAF-NH2), this simulating peptide is to pus
Toxication treatment does not have been reported that.
Present invention finds Reverse-D-4F can repair the EPCs function damage of LPS induction, suppression LPS lures
The EPCs apoptosis led, thus Reverse-D-4F is by mobilizing EPCs and repairing its function come to LPS induction
Rat Lung Injury is treated, and is an effectively treatment agent for the treatment of injury of lung, thus completes the present invention.
Content of the invention
The present invention relates to a kind of high-density protein simulating peptide Reverse-D-4F, its sequence is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
A kind of high-density protein simulating peptide Reverse-D-4F is in preparation treatment LPS Induced respiration Distress Syndrome
Medicine or test kit in application, the sequence of described high-density protein simulating peptide is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
A kind of high-density protein simulating peptide Reverse-D-4F is preparing endothelial progenitor cells reparation endothelial injury medicine
Or the application in test kit, the sequence of described high-density protein simulating peptide is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
A kind of high-density protein simulating peptide Reverse-D-4F is in preparation prevention or treatment injury of lung medicine or reagent
Application in box, the sequence of described high-density protein simulating peptide is Ac-FAEKFKEAVKDYFAKFWD-NH2.
A kind of high-density protein simulating peptide Reverse-D-4F is in preparation prevention or treatment medication for treating pyemia or reagent
Application in box, the sequence of described high-density protein simulating peptide is Ac-FAEKFKEAVKDYFAKFWD-NH2.
Wherein said injury of lung is pulmonary edema, and described test kit still further comprises adjuvant, and described adjuvant is hydrogen
Aluminum adjuvant, coryne bacterium parvum, lipopolysaccharide, cytokine or Alumen.
Present invention discover that proposing the pulmonary edema that Reverse-D-4F can suppress LPS induced rat model of lung injury,
Suppress the generation of internal inflammatory factor, suppress alveolar wall thickening, the infiltration of intercellular space erythrocyte and leukocyte, with
And the generation (ICAM-1, VCAM-1 and iNOS) of lung endothelium inflammatory markers, increase the mark (eNOS of endothelium
And vWF).Reverse-D-4F promotes LPS induced rat model of lung injury EPCs to mobilize, no matter in vitro
Still in vivo, Reverse-D-4F all can repair the function of LPS induced rat model of lung injury EPCs damage.
Brief description
It is that Reverse-D-4F can suppress the pulmonary edema of LPS induced rat model of lung injury with vivo shown in Fig. 1
The generation of inflammatory factor.
It is Reverse-D-4F suppression LPS induced rat model of lung injury alveolar wall thickening shown in Fig. 2, intercellular
Gap erythrocyte and the infiltration of leukocyte
It is Reverse-D-4F suppression LPS induced rat model of lung injury lung endothelium inflammation mark shown in Fig. 3
The generation (ICAM-1, VCAM-1 and iNOS) of will, and increase the mark (eNOS and vWF) of endothelium.
It is the EPCs that Reverse-D-4F mobilizes LPS induced rat model of lung injury shown in Fig. 4.
It is that Reverse-D-4F repairs the function that LPS induced rat model of lung injury EPCs damages shown in Fig. 5.
It is that Reverse-D-4F repairs the function that LPS induces EPCs to damage in vitro shown in Fig. 6.
Specific embodiment
Reverse-D-4F treats LPS induced rat model of lung injury.
Animal ARDS model is set up, and 24 male C57 mices are divided into 4 groups：
(1) matched group (lumbar injection PBS)；
(2) Reverse-D-4F group (lumbar injection Reverse-D-4F 10mg/Kg)
(3) model group (lumbar injection LPS 10mg/Kg)；
(4) Reverse-D-4F treatment group (lumbar injection Reverse-D-4F 10mg/Kg and LPS
10mg/Kg)
After modelling 2 days, put to death after ketalar intravenous injection general anesthesia, take left lung, lung tissue table
Face liquid absorbent paper is blotted only, and the weight weighing left lung is considered as weight in wet base；Left lung is placed on drying baker
60 DEG C of dryings 48 hours, then weighing weight is dry weight.Wet dry weight ratio is evaluating pulmonary edema degree.
Detect the expression of tumor necrosis factor-alpha and ET-1 in mice plasma with ELISA kit.
The lobus dexter of pulmonary all through 10% formalin fix, paraffin embedding, cut into slices 6 μm, then use hematoxylin-
Eosin stains.Carried out with specific antibody (VCAM-1, ICAM-1, iNOS, eNOS, vWF and Sca-1)
Immunohistochemical staining and HE dyeing.
Observe HE dyeing lung sections with 10 visuals field of high power lenses random choose, and the erythrocyte to infiltration and thin in vain
Born of the same parents count, and alveolar wall thickness are measured simultaneously.
Crack peripheral red blood cells with erythrocyte lysing buffer.Then antibody FITC-CD34 (BD), PE- are used
Flk-1, and APC-CD133 labelling cell.Flow cytometer showed positive cell number.
Sacrificed by decapitation after C57 mouse anesthesia, 75% ethanol soaks 15min, clip femur and tibia；Cold PBS
Liquid rinses medullary cavity repeatedly until flushing liquor is limpid, flushing liquor is blown and beaten repeatedly, 100 μm of strainer filtering Cheng Dan
Cell suspension；Flushing liquor is 2 000r/min centrifugation at 1: 1,20 DEG C with the volume ratio of Ficoll separating liquid
20min.Milky cloud mononuclearcell layer is in new centrifuge tube in the middle of gentle aspiration centrifuge tube, phosphoric acid
Salt buffer PBS washes cell precipitation 2 times；Complete culture solution re-suspended cell, repeatedly soft piping and druming make slender
Carry out cell counting after born of the same parents' suspension.By 106/cm2Density be seeded in advance use Fibronectin coated six
On orifice plate or culture bottle；After culture 3d, wash non-adherent cell off with PBS liquid, every 3d changes culture fluid one
Secondary.
The DiI-acLDL of EPCs and 2.5mg/L is incubated 2h at 37 DEG C；Then fixed with 1-2% paraformaldehyde
Cell 5min；After PBS embathes, add the FITC-UEA of 10mg/L, after 37 DEG C of incubation 1h, wash away many
After remaining dyestuff, neutral glycerine mounting, observed with fluorescence microscope or laser co-focusing；Display red fluorescence be
DiI-acLDL is positive, display green fluorescence positive for FITC-UEA-1, display yellow for the double fluorescence of immunity
The positive, being confirmed to be the double staining positive cells of DiI-acLDL and FITC-UEA is considered as to break up
EPCs.
It is inoculated in the culture plate completing fibronectin in advance after EPCs pancreatin is digested, incubate with culture fluid
Educate 30min, take 5 high power lenses (× 10) visuals field to count attached cell immediately.Cell is inoculated in and is covered with fiber
Connect in 96 orifice plates of albumen, 3000 cells are inoculated in every hole, after 24h, every hole adds MTT (5g/L) 20 μ L
37 DEG C are continued incubation 4h afterwards, abandon supernatant, each hole adds 150 μ L dimethyl sulfoxide (DMSO), room temperature is shaken
10min, microplate reader 492nm reads absorbance.
The EPC having digested is inoculated on the culture plate being covered with matrigel glue in advance, 37 DEG C, 5%CO2 training
After supporting 24 hours, micro- sem observation becomes blood vessel situation.
Migration with 8 μm of 24 orifice plate detection EPCs.Cell after different disposal, uses 0.25% trypsin
Digestion, 1.2 × 104Cell sap is respectively placed in epicoele.EGM-2MV culture medium is placed in lower room.37 DEG C of cultures 24
H, top cell is removed with cotton swab, and lower room is dyeed with DAPI.Five visuals field are selected to observe (× 10) migration at random
Cell counting.
Mononuclearcell 0.25% trypsinization of the culture bone marrow derived of 7 days, 103Cell is put
In 96 orifice plates.Every other day with 0.25% trypsinization and carry out cell counting.
Accompanying drawing 1 characterizes pulmonary edema and the body that Reverse-D-4F can suppress LPS induced rat model of lung injury
The production of interior inflammatory factor, mice is put to death after processing 48 hours through LPS or Rev-D4F, takes lung lobus sinister
Detection wet-dry ratio (A)；Take mice plasma detection ET-1 (B) and TNF-α (C) level.According to shown in Fig. 1,
In the chmice acute model of lung injury of LPS induction, pulmonary edema substantially increases, inflammatory factor TNF- in model blood
α and ET-1 substantially increases；After giving the treatment of high density lipoprotein simulating peptide Reverse-D-4F, mice edema caused by the lung disorder
Swollen substantially reduction, and in blood, the increase level of inflammatory factor TNF-α and ET-1 is substantially inhibited.
Accompanying drawing 2 is Reverse-D-4F suppression LPS induced rat model of lung injury alveolar wall thickening, intercellular space
Erythrocyte and the infiltration of leukocyte, the repair of the mice injury of lung that Rev-D4F induces to LPS.A, lung is right
Leaf carries out HE dyeing；B, measures alveolar wall thickness, with matched group for 100%, calculates each group alveolar wall respectively
The percentage ratio of thickness；C, each group chooses ten visual field number RBC number, finally takes its average；D, each group is chosen
Ten visual field number leukocyte counts, finally take its average.According to shown in Fig. 2, the chmice acute injury of lung of LPS induction
In model, alveolar wall thickness substantially increases, and erythrocyte and leukocyte infiltration substantially in alveole gap；Give
Hence it is evident that improving the above-mentioned performance of mice model of lung injury after Reverse-D-4F treatment.The mice of LPS induction is anxious
In property model of lung injury
Accompanying drawing 3 is Reverse-D-4F suppression LPS induced rat model of lung injury lung endothelium inflammatory markers
Generation (ICAM-1, VCAM-1 and iNOS), and increase the mark (eNOS and vWF) of endothelium.SABC
Each Indexs measure to lung tissue：ICAM-1, VCAM-1 and iNOS are lung endothelial inflammation marks, eNOS and
VWF is lung endothelial cell marker.According to shown in Fig. 3, in the chmice acute model of lung injury lung tissue of LPS induction
Inflammatory markers factor Ⅴ CAM-1, ICAM-1 and iNOS expression of endothelial injury substantially increases, and normally interior
Chrotoplast marker gene eNOS and vWF substantially reduces；Hence it is evident that reducing interior after giving Reverse-D-4F treatment
The expression of inflammatory markers factor Ⅴ CAM-1, ICAM-1 and iNOS of skin lesion wound, improves normal endothelial simultaneously
The expression of cell marker factor eNOS and vWF.
Accompanying drawing 4 is the EPCs that Reverse-D-4F mobilizes LPS induced rat model of lung injury, wherein, A,
CD34 in mouse peripheral blood+、FLK-1+、CD133+、CD34+/FLK-1+、FLK-1+/CD133+And CD34+
/CD133+Each subgroup percentage ratio (NS is 100%)；B, SABC contaminates progenitor cell marker Sca-1, detects lung
Tissue progenitor cells are gone back to the nest situation.According to shown in Fig. 4, LPS can mobilize stem cell to peripheral blood, such as CD34+、
FLK-1+、CD133+、CD34/FLK-1+、FLK-1/CD133+And CD34/CD133+Cell is obvious
Increase, lung tissue carries stem-cell marker factor S ca-1+Cell also substantially increase；Give
After Reverse-D-4F treatment, peripheral blood CD34+、CD34/FLK-1+And CD34/CD133+The increasing of cell
Plus be substantially inhibited, and FLK-1+、CD133+And FLK-1/CD133+With endothelial progenitor cells mark
Cell increase further, Sca-1 in lung tissue+Cell quantity increases to repair LPS induction further
Injury of lung.
Accompanying drawing 5 characterizes Reverse-D-4F and repairs the function that LPS induced rat model of lung injury EPCs damages.
Each group mouse bone marrow cells are taken to be induced to differentiate into EPCs and detect its function：A, each group bone marrow mononuclear cells with
106/cm2It is inoculated in six well culture plates, after 3 days, removes non-adherent cell, attached cell is chosen five visuals field and carries out
Cell counting, then each group take average；B, after the induction differentiation EPCs pancreatin digestion of each group bone marrow cells in mice,
12000 cells are taken to be inoculated in room on migration cell, after lower room adds EGM-2MV to induce 24 hours, DAPI
Dyeing, chooses and counts under five visual field fluorescence microscopies；C, each group bone marrow cells in mice induction differentiation EPCs
Carry out adsorbing low density lipoprotein, LDL (red) and (green) experiment of binding lectin, choose five visual field fluorescence
Basis of microscopic observation, double positive cells account for the percentage ratio of all cells；D, each group bone marrow mononuclear cells
Culture 7 days, pancreatin digests, and is inoculated in 96 orifice plates with 1000 cells in every hole, and cell counted one every 1 day
Secondary.According to shown in Fig. 5, separate groups of mice bone marrow takes out and is induced to differentiate into EPCs, and detects its function, knot
Fruit finds that the cell number of model group mice EPCs differentiation reduces, although model group EPCs can be bred rapidly, its
Adhesive capacity and transfer ability have declined compared with matched group；After giving Reverse-D-4F treatment, mouse bone marrow cells
The quantity that mononuclearcell is divided into EPCs increased, and the damage of its adhesion and shift function is also repaiied
Multiple.
Accompanying drawing 6 characterizes Reverse-D-4F and repairs the function that LPS induces EPCs to damage in vitro, wherein, A,
MTT detects each group EPCs vigor, with the OD value of matched group for 100%；B, migration cell method detection each group
The transfer ability of EPCs；C, Matrigel gel method detects the external one-tenth vessel patency of EPCs.According to Fig. 6
Shown in vitro study, LPS (30 μ g/ml) substantially damages the work(that propagation, migration and the extracorporeal blood vessel of EPCs generate
Can, and Reverse-D-4F can substantially repair the damage that LPS induces above-mentioned functions, with LY294002 (PI3K
Inhibitor) the substantially suppression repair to EPCs function damage for the Reverse-D-4F.
Claims (8)
1. a kind of high-density protein simulating peptide Reverse-D-4F, its sequence is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
2. a kind of high-density protein simulating peptide Reverse-D-4F is in preparation treatment LPS Induced respiration Distress Syndrome
Application in medicine or test kit, the sequence of described high-density protein simulating peptide is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
3. a kind of high-density protein simulating peptide Reverse-D-4F prepare endothelial progenitor cells repair endothelial injury medicine or
Application in test kit, the sequence of described high-density protein simulating peptide is
Ac-FAEKFKEAVKDYFAKFWD-NH2.
4. a kind of high-density protein simulating peptide Reverse-D-4F is in preparation prevention or treatment injury of lung medicine or test kit
In application, the sequence of described high-density protein simulating peptide is Ac-FAEKFKEAVKDYFAKFWD-NH2.
5. a kind of high-density protein simulating peptide Reverse-D-4F is in preparation prevention or treatment medication for treating pyemia or test kit
In application, the sequence of described high-density protein simulating peptide is Ac-FAEKFKEAVKDYFAKFWD-NH2.
6. apply as claimed in claim 4, wherein said injury of lung is pulmonary edema.
7. the application as described in claim 2-6, wherein said test kit still further comprises adjuvant.
8. apply as claimed in claim 7, wherein adjuvant be aluminum hydroxide adjuvant, coryne bacterium parvum, lipopolysaccharide,
Cytokine or Alumen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610181324.9A CN106397541A (en) | 2016-03-25 | 2016-03-25 | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610181324.9A CN106397541A (en) | 2016-03-25 | 2016-03-25 | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106397541A true CN106397541A (en) | 2017-02-15 |
Family
ID=58007058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610181324.9A Pending CN106397541A (en) | 2016-03-25 | 2016-03-25 | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106397541A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111973633A (en) * | 2020-09-09 | 2020-11-24 | 中国人民解放军总医院 | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease |
| CN112386709A (en) * | 2019-08-16 | 2021-02-23 | 上海交通大学医学院 | Targeting polypeptide modified drug-loaded lipoprotein nano drug delivery system and preparation and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623629A (en) * | 2015-01-23 | 2015-05-20 | 泰山医学院 | Application of high-density lipoprotein in medicine used for mobilizing endothelial progenitor cells to repair endothelial injury |
-
2016
- 2016-03-25 CN CN201610181324.9A patent/CN106397541A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623629A (en) * | 2015-01-23 | 2015-05-20 | 泰山医学院 | Application of high-density lipoprotein in medicine used for mobilizing endothelial progenitor cells to repair endothelial injury |
Non-Patent Citations (3)
| Title |
|---|
| NANA YANG等: "Apolipoprotein A-I mimetic peptide reverse D-4F improves the biological functions of mouse bone marrow-derived late EPCs via PI3K/AKT/eNOS pathway", 《MOL CELL BIOCHEM》 * |
| YANG NANA等: "Reverse-D-4F Increases the Number of Endothelial Progenitor Cells and Improves Endothelial Progenitor Cell Dysfunctions in High Fat Diet Mice", 《PLOS ONE》 * |
| 毛梅: "内皮祖细胞移植修复肺血管内皮炎症损伤的实验研究", 《中国博士学位论文全文数据库（电子期刊）医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112386709A (en) * | 2019-08-16 | 2021-02-23 | 上海交通大学医学院 | Targeting polypeptide modified drug-loaded lipoprotein nano drug delivery system and preparation and application thereof |
| CN112386709B (en) * | 2019-08-16 | 2022-03-08 | 上海交通大学医学院 | Targeting polypeptide modified drug-loaded lipoprotein nano drug delivery system and preparation and application thereof |
| CN111973633A (en) * | 2020-09-09 | 2020-11-24 | 中国人民解放军总医院 | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Decellularization and recellularization of rat livers with hepatocytes and endothelial progenitor cells | |
| CN106109496B (en) | Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method | |
| Lu et al. | Self‐supporting graphene hydrogel film as an experimental platform to evaluate the potential of graphene for bone regeneration | |
| Ahmed et al. | Role of bone marrow mesenchymal stem cells in the treatment of CCL4 induced liver fibrosis in albino rats: a histological and immunohistochemical study | |
| Guan et al. | Porcine kidneys as a source of ECM scaffold for kidney regeneration | |
| CN104302763B (en) | Stroma stem cell | |
| CN108310014B (en) | Stem cell preparation, preparation method thereof and application of stem cell preparation in preparation of drugs for preventing and treating lung injury | |
| CN110295142A (en) | Promote the mesenchymal stem cell excretion body and its preparation method and application of angiogenesis | |
| Wang et al. | Comparison of in vivo adipogenic capabilities of two different extracellular matrix microparticle scaffolds | |
| van der Helm et al. | Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers | |
| CN109745341A (en) | Ferroso-ferric oxide superparamagnetic nano particle stimulates stem cell excretion body skeletonization | |
| CN106397541A (en) | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome | |
| CN106038597A (en) | Application of mesenchyma stem cells to preparation of acute lung injury treating preparation | |
| Li et al. | When stem cells meet COVID-19: recent advances, challenges and future perspectives | |
| CN113521104A (en) | Application of mesenchymal stem cells in combination with PRP (platelet-rich plasma) in preparation of medicine for treating knee joint cartilage injury and osteoarthritis | |
| CN107496413A (en) | Application of the mangiferin in the medicine for promoting bone defect healing is prepared | |
| CN107349220A (en) | A kind of preparation comprising fibroblast excretion body and application thereof | |
| da Silva da Costa et al. | Three-dimensional cell cultures as a research platform in lung diseases and COVID-19 | |
| CN105395533A (en) | Application of sodium butyrate in preventing and curing high permeability of blood vessels and relevant diseases | |
| Shen et al. | Therapeutic benefits of CD 90‐negative cardiac stromal cells in rats with a 30‐day chronic infarct | |
| Deng et al. | A Senomorphic‐Conjugated Scaffold for Application of Senescent Cells in Regenerative Medicine | |
| CN106333965B (en) | A kind of preparation that treating Osteoarthritis and treatment method | |
| Abreu et al. | Serum from patients with asthma potentiates macrophage phagocytosis and human mesenchymal stromal cell therapy in experimental allergic asthma | |
| Gupta et al. | Microscopic study of aorta in relation of different age groups: an observational study | |
| CN107653223A (en) | A kind of amnion stem cell media and its cultural method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |
|
| RJ01 | Rejection of invention patent application after publication |